On 30 October 2026 the U.S. Food and Drug Administration (FDA) granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP). The approval is the first in the United States for a plasmid DNA-based immunotherapy, and it gives a small patient group a non-surgical option against a disease that is currently managed, in most cases, by operating again and again. The approval was granted to Inovio Pharmaceuticals, Inc., and it covers the treatment given together with the CELLECTRA 5PSP delivery device.
A Disease Defined by Repeat Surgery
RRP is a rare, chronic disease in which wart-like growths called papillomas, caused by human papillomavirus (HPV) types 6 and 11, form in the airways, most often around the larynx, or voice box, and particularly the vocal cords. The growths can cause hoarseness, chronic cough and voice changes, and in severe cases they can spread and cause difficulty breathing. Surgery can remove the growths, but there is no cure, and the virus persists in tissue even after removal, so patients often need repeated procedures over many years. In some cases RRP carries a risk of becoming cancerous over time.
How Voceryq Works
Voceryq is a recombinant plasmid DNA-based immunotherapy that delivers two plasmids, small pieces of DNA, into the body's cells. One carries the genetic instructions for specific HPV proteins, and the other carries instructions for interleukin-12 (IL-12), a molecule that enhances the immune response. The treatment is designed to prompt the immune system to attack cells infected by HPV types 6 and 11. It is given by intramuscular injection using the CELLECTRA 5PSP device, which uses electroporation, brief electrical pulses that temporarily open pores in cell membranes so the treatment can enter cells. Treatment follows a 9-week dosing regimen, after a standard surgical removal of visible papillomas before the first dose.
What the Trial Showed
The FDA based its decision on an open-label, multicentre trial in 32 adults with RRP, all of whom had two or more surgeries to remove laryngotracheal papillomas in the 12 months before treatment. The efficacy population was 26 patients who had at least three baseline surgeries, with a median of 4.5 surgeries in the year before treatment. Seven of those 26 patients, 27 percent (95 percent confidence interval, 12 to 48 percent), needed no surgical intervention during the first year after treatment, an outcome defined as a complete response. The trial had no control arm, and the FDA approved the treatment on an intermediate endpoint, reduced surgery frequency, that it considers reasonably likely to predict clinical benefit. Because the approval is accelerated, the manufacturer must run post-approval trials to verify that benefit, and continued approval may depend on those findings. Inovio says it must submit a draft protocol for a confirmatory study by the end of 2026, with final protocol alignment expected by mid-2027.
On safety, the most commonly reported adverse reactions were injection site reactions, headache, fatigue, high blood pressure, nausea and dizziness. Inovio reports that most treatment-related reactions were grade 1 or 2 and transient, with no grade 4 or 5 common adverse events. Effects linked to electroporation may include brief muscle contractions, temporary bleeding, anxiety, vasovagal reactions, skin redness and pain at the injection site. The manufacturer advises monitoring patients for at least 30 minutes after each treatment, avoiding the device on the same side as an implanted cardioverter-defibrillator or pacemaker, and avoiding sites with metal implants or skin abnormalities. The FDA had previously granted Voceryq Breakthrough Therapy and Orphan Drug designations. It is the second immunotherapy for RRP after Papzimeos, approved in August 2025, but the first to use plasmid DNA.
Why This Matters for Healthcare Organizations
For ear, nose and throat practices and the specialty clinics that follow these patients, the approval changes the shape of care rather than removing surgery overnight. A patient starting Voceryq needs a planned surgical removal first, then a 9-week course of device-assisted injections with monitoring after each dose, plus a team trained to run the delivery device. Referral timing matters, since patients with hoarseness or voice change may first present in primary care and need a timely specialist assessment. Practices should also be careful in how they describe the option: the evidence comes from a small, open-label trial with no control arm, the benefit is measured as fewer surgeries rather than a cure, and the confirmatory trial has not yet run. Neither announcement addresses pricing or coverage for individual patients, so payer conversations remain open.
Analysis: Early Access, With Proof Still to Come
Accelerated approval is a trade, and this case shows both sides of it clearly. Patients get access years before a large confirmatory trial could finish, but on the basis of 26 patients in an efficacy population and a single year of surgery-free follow-up. That is a thin base for strong claims, and the FDA has kept the strings attached: a confirmatory trial, a draft protocol by the end of 2026, and approval that can be revisited if benefit is not verified. Inovio calls Voceryq the first FDA-approved DNA medicine, a company claim about the technology rather than a finding about this disease. The fair reading is narrower and still meaningful. A second, differently built immunotherapy now exists for a disease where surgery was the default, and the next evidence will decide how far that option reaches.
Clinics adding new treatment pathways and the appointment, screening and follow-up work that comes with them can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote for their own practice.
Sources and References
- U.S. Food and Drug Administration — FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis, 30 October 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis
- Inovio Pharmaceuticals via PR Newswire — INOVIO Announces FDA Accelerated Approval of VOCERYQ, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP), 30 October 2026: https://ir.inovio.com/news/news-details/2026/INOVIO-Announces-FDA-Accelerated-Approval-of-VOCERYQ-an-Immunotherapy-to-Reduce-the-Frequency-of-Surgery-in-Adults-with-Recurrent-Respiratory-Papillomatosis-RRP/default.aspx
- HCPLive — Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis, 30 October 2026: https://www.hcplive.com/view/voceryq-gains-fda-accelerated-approval-for-recurrent-respiratory-papillomatosis
Reporting based on the sources above, accessed 1 November 2026. The FDA announcement, the Inovio announcement and the HCPLive report were read directly in full and cross-checked against each other. MedClinicX did not conduct original reporting or interviews for this article. This article is for information only and is not medical advice. Corrections: contact us via https://medclinicx.com/contact